Summary
Quazepam has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Insomnia / Sleep Disorders would be drug repurposing rather than first-in-human development. This does not mean it is approved for Insomnia / Sleep Disorders. No registered clinical trial in this database tests Quazepam specifically in Insomnia / Sleep Disorders. The evidence below comes from published literature only, so any clinical signal has not yet been tested prospectively against this condition in a registered study. The literature layer holds 8 publications for this pair: 2 Cochrane reviews, 1 randomised controlled trial publication and 5 clinical trial publications. Publication years run from 1991 to 2020. Because at least one synthesis-level source exists (systematic review, meta-analysis or Cochrane review), this pair has been assessed beyond single studies, although the synthesis may concern a different indication.
The RepurpOS disease-intelligence file for Insomnia ranks 317 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: Acute insomnia (<3 months): 50-60% resolve spontaneously; chronic insomnia: only 20-25% spontaneous remission at 1 year; persistent insomnia in 50-75% without treatment.
Evidence table
| Evidence tier | A · Strong |
|---|---|
| Evidence score | 43.0 (trials 0.0, literature 23.0, tier 15, approved bonus 5.0) |
| Registered trials | 0 total: 0 recruiting, 0 active / not yet recruiting, 0 completed, 0 other |
| Linked publications | 8 (5 clinical trial publications, 2 Cochrane reviews, 1 randomised controlled trial publication) |
| Agent type | Drug (Small molecule) |
| Development stage (any indication) | Approved |
| Mechanism / class | Not recorded |
| Data sources | Open Targets, ChEMBL |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
No registered trial links Quazepam to Insomnia / Sleep Disorders in the current OSMF trial extract.
Published literature
- Cochrane review Pharmacological interventions for the treatment of insomnia: quantitative comparison of drug efficacyZheng X, He Y, Yin F et al. · Sleep medicine · 2020 · PMID 32544795
- Clinical trial publication Effects of quazepam as a preoperative night hypnotic: comparison with brotizolamNishiyama T, Yamashita K, Yokoyama T et al. · Journal of anesthesia · 2007 · PMID 17285406
- Cochrane review Insomnia in the elderlyMontgomery P, Lilly J · BMJ clinical evidence · 2007 · PMID 19450355
- Clinical trial publication Hypnotic effects of low doses of quazepam in older insomniacsRoth TG, Roehrs TA, Koshorek GL et al. · Journal of clinical psychopharmacology · 1997 · PMID 9315991
- Clinical trial publication Evaluation of the safety and efficacy of quazepam for the treatment of insomnia in psychiatric outpatientsMendels J · The Journal of clinical psychiatry · 1994 · PMID 7915708
- Clinical trial publication Insomnia in generalized anxiety disorder: polysomnographic, psychometric and clinical investigations before, during and after therapy with a long- versus a short-half-life benzodiazepine (quazepam versus triazolam)Saletu B, Anderer P, Brandstätter N et al. · Neuropsychobiology · 1994 · PMID 8170529
- Clinical trial publication Feasibility of an every-other-night regimen in insomniac patients: subjective hypnotic effectiveness of quazepam, triazolam, and placeboScharf MB · The Journal of clinical psychiatry · 1993 · PMID 8428895
- Randomized controlled trial Objective measurements of daytime sleepiness and performance comparing quazepam with flurazepam in two adult populations using the Multiple Sleep Latency TestDement WC · The Journal of clinical psychiatry · 1991 · PMID 1680123
Mechanism and notes
No mechanism of action is recorded for this pair in the source databases.
OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in Open Targets and ChEMBL. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Quazepam approved for Insomnia / Sleep Disorders?
Quazepam has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Insomnia / Sleep Disorders would be drug repurposing rather than first-in-human development. This does not mean it is approved for Insomnia / Sleep Disorders. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Quazepam in clinical trials for Insomnia / Sleep Disorders?
No registered clinical trial in this database tests Quazepam specifically in Insomnia / Sleep Disorders. The evidence below comes from published literature only, so any clinical signal has not yet been tested prospectively against this condition in a registered study.
What does the evidence show for Quazepam in Insomnia / Sleep Disorders?
Synthesis-level literature links Quazepam to Insomnia / Sleep Disorders, but no registered trial in this database tests the pair, so the evidence is observational, pooled from other indications, or pre-dates registry practice. OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in Open Targets and ChEMBL. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-05. Page built 2026-10-07.